I downloaded the pdf announcement from AVXL's website and this is what is at the top of the document:
Investigational Treatment suggests to curb Cognitive and Functional Decline - Full data to be presented at CTAD 2016 - NEW YORK, NY – November 22, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL) today announced a positive 41-week update from its Phase 2a study in mild-to-moderate Alzheimer’s disease (AD) patients for ANAVEX 2-73, which targets cellular homeostasis.